NASHVILLE, TN
October 1-3, 2018
Hutton Hotel

A SUMMIT TO CONNECT THE DATA AND DIGITAL INFRASTRUCTURE NEEDED TO ENABLE PRECISION MEDICINE AT SCALE

Stakeholders across the healthcare system face significant barriers to the effective implementation of precision medicine.

Solutions must carefully consider the practical realities of a complex, multi-stakeholder environment.

This Summit provides influential leaders a candid, collaborative forum to define and implement solutions that connect the genetic health information network.

An intimate meeting of influential leaders from across in the Genetic Health Information Network

Representing all stakeholders in this ecosystem, including
  • Health plans
  • Clinicians
  • Hospital systems
  • Researchers
  • Policy makers
  • Patients & Advocates
  • Laboratories
  • IT Vendors
  • Pharma

2018 Organizing Committee

Alphabetical order
Gil Alterovitz, MD

Director, Biomedical Cybernetics Laboratory

Harvard Medical School

Kristine Bordenave, MD

Corporate Medical Director

Humana

Carlos Bustamante, PhD

Chair, Department of Biomedical Data Science

Stanford University

Joshua Denny, MD

Professor of Biomedical Informatics and Medicine

Vanderbilt University

Henry Garlich

Director, Healthcare Value Solutions & Enhanced Clinical Programs

Blue Shield of California

Trent Haywood, MD, JD

SVP & Chief Medical Officer

Blue Cross Blue Shield Association

Gillian Hooker, PhD, ScM, LCGC

VP, Clinical Development

Concert Genetics

Howard Levy, MD, PhD

Associate Professor of Medicine

Johns Hopkins Medicine

Matt Might, PHD

Director, Hugh Kaul Personalized Medicine Institute

University of Alabama at Birmingham

Robert Nussbaum, MD

Chief Medical Officer

Invitae

Julie Ramage

National Accounts Director, Diagnostics

Pfizer

Benjamin Solomon, MD

Managing Director

GeneDx

The only multi-stakeholder gathering focused on solving the data, digital infrastructure, and economic challenges facing precision medicine

Intimate, carefully curated, invitation-only gathering

Full spectrum of stakeholders

Focused on needs and solutions

Collaborative, discussion-oriented format

Chatham-house rules — non-attribution

No sponsored talks, sales pitches or marketing lists

Published conference summary and recommendations

Identify and resolve practical barriers facing precision medicine by

  • Improving the capture of clinical effectiveness and economic value data
  • Simplifying the test ordering and resulting workflow for clinicians, hospitals and labs
  • Streamlining the genetic test billing, adjudication and payment process
  • Reducing the frequency of misordered tests and surprise bills for patients
  • Empowering patients to harness the insights in their genetic makeup for greater health

Speakers & Panelists

Click here for agenda and session descriptions

Trent Haywood, MD, JD

SVP & Chief Medical Officer

Blue Cross Blue Shield Association

Robert Nussbaum, MD

Chief Medical Officer

Invitae

Laurie McGraw

SVP, Health Solutions

American Medical Association

Carlos Bustamante, PhD

Chair, Department of Biomedical Data Science

Stanford University

Victoria Pratt, PhD

President-elect

Association for Molecular Pathology

Howard Levy, MD, PhD

Associate Professor of Medicine

Johns Hopkins Medicine

Dawn Barry

Co-Founder and President

Luna DNA

Eli Casdin

Chief Investment Officer

Casdin Capital

Ellen Matloff, MS, CGC

President & CEO

My Gene Counsel

Julie Eggington, MS, PhD

Co-Founder & CEO

Center for Genomic Interpretation

Alex De Winter

Managing Director

GE Ventures

Emily Edelman, MS, CGC

Associate Director of Clinical & Continuing Education

The Jackson Laboratory

Henry Garlich

Director, Healthcare Value Solutions & Enhanced Clinical Programs

Blue Shield of California

Matt Might, PhD

Director, Hugh Kaul Personalized Medicine Institute

University of Alabama at Birmingham

+78 Net Promoter Score

This Summit is back by popular demand thanks to the enthusiastic response of last year’s participants.

“Intimate engagement with key stakeholders in the genomic medicine space that does not otherwise happen all that often…Excellent and efficient organization and moderation with summary of key points throughout.”

  • Director, Molecular Pathology

“Excellent speakers, panels, participants, and facilitation on relevant topics”

  • CEO, genomics company

“It was a unique and diverse group of stakeholders with (most importantly) time to interact with each other. Key gaps that need to be bridged were openly discussed and at least understood, if not resolved.”

  • Chief Medical Officer

“I thought that the summit raised important issues and brought together interested and diverse individuals to exchange ideas and propose serious solutions to real problems in the field.”

  • President, advocacy organization

“Open discussion, and a focus on actionable takeaways. Attendance by people who are influential.”

  • Director, Science Policy
This event is by invitation only. If you would like to nominate somebody, including yourself, to participate in the summit, please complete the following form: